Iovance Biotherapeutics Quarterly Balance Sheet
NASDAQ: IOVAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Iovance Biotherapeutics financial position
As of Jun 30, 2026, Iovance Biotherapeutics reported total assets of $915.5 million, up 0.9% from a year earlier against total liabilities of $179.5 million. Shareholders' equity stood at $736.0 million, or 80.4% of assets. The company held $110.8 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 4.35, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Iovance Biotherapeutics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 110.77M | 196.51M | 163.08M | 158.13M | 132.47M | 171.67M | 115.69M | 164.19M | 228.68M | 134.19M | 114.89M | 267.72M |
| Short-Term Investments | 186.91M | 116.94M | 133.90M | 142.67M | 168.71M | 188.04M | 208.09M | 233.30M | 183.86M | 222.01M | 164.98M | 93.65M |
| Receivables | 102.12M | 81.76M | 82.45M | 66.76M | 59.94M | 70.94M | 69.34M | 55.77M | 31.60M | 234.00K | 151.00K | — |
| Inventory | 55.59M | 58.38M | 51.68M | 51.71M | 49.83M | 65.55M | 51.52M | 38.58M | 27.85M | 17.62M | 10.37M | 9.20M |
| Total Current Assets | 464.26M | 466.50M | 442.69M | 429.09M | 422.50M | 512.65M | 457.02M | 498.58M | 482.26M | 385.53M | 307.85M | 382.59M |
| Property, Plant & Equipment | 131.46M | 131.39M | 131.11M | 126.65M | 122.47M | 111.58M | 109.08M | 112.52M | 110.96M | 111.79M | 114.03M | 113.14M |
| Intangible Assets | 263.89M | 269.10M | 279.32M | 285.21M | 296.25M | 285.36M | 282.40M | 306.64M | 295.30M | 294.30M | 229.26M | 223.61M |
| Total Assets | 915.53M | 925.66M | 913.17M | 904.95M | 907.44M | 966.74M | 910.43M | 991.12M | 964.32M | 869.83M | 780.35M | 852.32M |
| Accounts Payable | 26.21M | 37.45M | 22.16M | 31.24M | 32.00M | 28.49M | 27.51M | 31.69M | 20.42M | 25.70M | 33.12M | 19.27M |
| Total Current Liabilities | 106.85M | 129.42M | 138.36M | 125.78M | 129.16M | 122.69M | 122.34M | 118.06M | 93.64M | 83.21M | 110.31M | 90.95M |
| Long-Term Debt | — | — | — | — | — | — | 1.00M | 1.00M | 1.00M | 1.00M | 1.00M | 1.00M |
| Total Liabilities | 179.49M | 203.91M | 214.59M | 202.66M | 208.95M | 198.88M | 200.02M | 217.66M | 195.78M | 189.81M | 195.74M | 178.31M |
| Shareholders' Equity | 736.04M | 721.75M | 698.58M | 702.29M | 698.49M | 767.87M | 710.40M | 773.46M | 768.54M | 680.02M | 584.61M | 674.01M |
| Retained Earnings | -2.90B | -2.85B | -2.78B | -2.70B | -2.61B | -2.50B | -2.38B | -2.31B | -2.22B | -2.13B | -2.01B | -1.90B |
| Total Debt | — | — | — | — | — | — | 1.00M | 1.00M | 1.00M | 1.00M | 1.00M | 1.00M |
| Net Cash (Debt) | 297.67M | 313.44M | 296.98M | 300.80M | 301.18M | 359.71M | 322.78M | 396.49M | 411.54M | 355.19M | 278.87M | 360.37M |
| Shares Outstanding | 452.97M | 438.11M | 411.94M | 385.46M | 341.92M | 333.93M | 305.25M | 304.62M | 297.31M | 279.76M | 256.14M | 255.83M |
This table shows 12 quarterly periods of Iovance Biotherapeutics's balance sheet, from Q2 2026 back to Q3 2023, across 18 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow IOVA's reporting calendar. What is a balance sheet?